Fortress Biotech Stock Quote FBIO - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.65

Bid

1.57

Ask

1.70

Volume

376,229

1.55 Day's Range 1.6288

1.355 52 Week Range 4.43

Market Cap

45.548M

Previous Close

1.59

Open

1.615

Last Trade

554

1.65

(formt)

Last Trade Time

Financial Volume

$ 594,029

VWAP

1.5789

Average Volume (3m)

609,490

Shares Outstanding

27,604,934

Dividend Yield

PE Ratio

-0.63

Earnings Per Share (EPS)

-2.49

Revenue

84.51M

Net Profit

-68.67M

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the g... Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Targadox, Exelderm, Ceracade, Luxamend, and Dermasorb. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology, therapeutics sectors. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.fortressbiotech.com

Headquarters

Dover, Delaware, USA

Founded

Fortress Biotech Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker FBIO. The last closing price for Fortress Biotech was $1.59. Over the last year, Fortress Biotech shares have traded in a share price range of $ 1.355 to $ 4.43.

Fortress Biotech currently has 27,604,934 shares outstanding. The market capitalization of Fortress Biotech is $43.89 million. Fortress Biotech has a price to earnings ratio (PE ratio) of -0.63.

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or...

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization...

Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of...

Mustang Bio Receives Positive Listing Determination from Nasdaq

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...

Mustang Bio Granted Orphan Drug Designation by U.S. FDA for MB-108 (HSV-1 oncolytic virus) to Treat Malignant Glioma

MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...

Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.05	-2.94117647059	1.7	1.74	1.41	504672	1.52742323	CS
4	-0.16	-8.83977900552	1.81	2.1	1.41	583902	1.76820548	CS
12	-0.39	-19.1176470588	2.04	2.1	1.355	609490	1.64953186	CS
26	-0.24	-12.6984126984	1.89	2.89	1.355	410474	1.76191568	CS
52	-0.63	-27.6315789474	2.28	4.43	1.355	441082	2.07436369	CS
156	-44.4	-96.4169381107	46.05	46.725	1.24	492005	10.35214673	CS
260	-26.25	-94.0860215054	27.9	91.5	1.24	656812	34.08871037	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
FBRXForte Biosciences Inc	$ 13.60 (129.53%)	28.92M
QSIQuantum Si Inc	$ 1.39 (119.59%)	279.33M
XCURExicure Inc	$ 11.01 (89.18%)	22.91M
AGFYAgrify Corporation	$ 37.4635 (68.00%)	921.45k
SLXNSilexion Therapeutics Corporation	$ 0.3495 (54.51%)	198.66M
SKKSKK Holdings Limited	$ 4.55 (-47.28%)	816.93k
QMMMQMMM Holdings Limited	$ 0.713999 (-43.78%)	4.61M
XTKGX3 Holdings Company Ltd	$ 0.0901 (-37.82%)	5.95M
PRFXPainReform Ltd	$ 1.02 (-27.14%)	5.09M
GLEGlobal Engine Group Holding Ltd	$ 3.81 (-26.59%)	230.23k
TNXPTonix Pharmaceuticals Holding Corporation	$ 0.191 (17.39%)	662.68M
DBGIDigital Brands Group Inc	$ 0.1345 (15.35%)	326.45M
NVDANVIDIA Corporation	$ 145.89 (-0.76%)	309.57M
QSIQuantum Si Inc	$ 1.39 (119.59%)	283.09M
SLXNSilexion Therapeutics Corporation	$ 0.3495 (54.51%)	200.06M